In particular, the almost $170 million commitment to making Long-Acting Reversible Contraceptives (LARCs) such as IUD’s more widely available is a “hugely positive move,” she said.
Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the activated form ...